BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

19 related articles for article (PubMed ID: 38679489)

  • 1. Letter: Role of Spironolactone in Preventing Contrast-Induced Nephropathy.
    Ozbay MB; Degirmen S; Iqbal P; Nriagu BN; Abdealmottaleb W
    Angiology; 2024 Jun; ():33197241263383. PubMed ID: 38886180
    [No Abstract]   [Full Text] [Related]  

  • 2. Combined impact of chronic kidney disease and contrast-induced nephropathy on long-term outcomes in patients with ST-segment elevation acute myocardial infarction who undergo primary percutaneous coronary intervention.
    Nakahashi H; Kosuge M; Sakamaki K; Kiyokuni M; Ebina T; Hibi K; Tsukahara K; Iwahashi N; Kuji S; Oba MS; Umemura S; Kimura K
    Heart Vessels; 2017 Jan; 32(1):22-29. PubMed ID: 27106917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk stratification according to the type of impaired renal function in patients with acute myocardial infarction treated with percutaneous coronary intervention.
    Kowalczyk J; Lenarczyk R; Kowalski O; Swiatkowski A; Stabryła-Deska J; Kurek T; Honisz G; Kukulski T; Gasior M; Kalarus Z
    Kardiol Pol; 2007 Jun; 65(6):635-43; discussion 644. PubMed ID: 17629825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Contrast-Induced Nephropathy in STEMI Patients With and Without Chronic Kidney Disease.
    Jain T; Shah S; Shah J; Jacobsen G; Khandelwal A
    Crit Pathw Cardiol; 2018 Mar; 17(1):25-31. PubMed ID: 29432373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spironolactone Improves the All-Cause Mortality and Re-Hospitalization Rates in Acute Myocardial Infarction with Chronic Kidney Disease Patients.
    Qu X; Yao H; Chen C; Kong S; Sun L; Du L; Liang S; Gao Z; Zheng G; Zheng M; Zhao C; Feng X; Wu G; Zhou H
    Front Pharmacol; 2021; 12():632978. PubMed ID: 34135751
    [No Abstract]   [Full Text] [Related]  

  • 6. Effect of Vigileo/FloTrac System-Guided Aggressive Hydration in Acute Myocardial Infarction Patients to Prevent Contrast-Induced Nephropathy After Urgent Percutaneous Coronary Intervention.
    Ling W; Jiang Z; Liu K; Zhang H; Qian Y; Tian J; Zhang Z; Chen Y; Qian G
    Am J Cardiol; 2023 May; 195():77-82. PubMed ID: 37018968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone for Preventing Contrast-Induced Nephropathy After Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction and Chronic Kidney Disease.
    Lu Y; Ni W; Qu X; Chen C; Shi S; Guo K; Lin K; Zhou H
    Angiology; 2024 Apr; ():33197241251889. PubMed ID: 38679489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of short-term moderate or high-dose rosuvastatin in preventing contrast-induced nephropathy: A meta-analysis of 15 randomized controlled trials.
    Liang M; Yang S; Fu N
    Medicine (Baltimore); 2017 Jul; 96(27):e7384. PubMed ID: 28682890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and Predictors of Contrast-Induced Nephropathy (CIN) in Patients with ST-Segment Elevation Myocardial Infarction (STEMI) Undergoing Percutaneous Coronary Intervention (PCI): A Meta-Analysis.
    He H; Chen XR; Chen YQ; Niu TS; Liao YM
    J Interv Cardiol; 2019; 2019():2750173. PubMed ID: 31772520
    [TBL] [Abstract][Full Text] [Related]  

  • 10.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 11.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 12.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 1.